Terapet announces international collaboration for Heavy Ion Therapy QA
Terapet SA are proud to announce an international collaboration to develop a world-first device for patient-specific QA in heavy ion therapy (HIT). Terapet will be joined in the collaboration by Korean partners Yonsei Cancer Center and Oncosoft Inc, who together bring vital medical expertise and software innovations to be united with Terapet’s novel nuclear imaging technology. The project, worth almost CHF 3’000’000 over the next 3 years, is funded by a bilateral grant from the Korea Institute for Advancement of Technology (KIAT) and the Swiss Innovation Agency (Innosuisse).
The collaboration agreement was signed during the FARO-KOSRO 2023 congress in Seoul, Korea. Terapet’s CEO, Christina Vallgren, welcomed the collaboration, saying “Together, we’re not just merging resources; we’re uniting our strengths across two countries and continents, making a real impact for the future of heavy ion therapy.”
A full press release is attached.
Linkedin post here.